西格列汀对于新诊断2型糖尿病的临床分析  

Clinical Analysis of New Type 2 Diabetes Mellitus With Sitagliptin

作　　者：赵文萍[1] 李婷[1] 何晓彤[1] 孙中华[1] 

机构地区：[1]吉林大学第一医院内分泌科,长春130021

出　　处：《中国继续医学教育》2015年第28期121-122,共2页China Continuing Medical Education

摘　　要：目的探讨西格列汀治疗新诊断2型糖尿病的疗效及安全性。方法选取新诊断2型糖尿病患者74例,分为对照组(二甲双胍治疗)37例、观察组(西格列汀治疗)37例。对比两组患者治疗前后空腹血糖(FPG)、餐后2h血糖(2h PG)、糖化血红蛋白(Hb A1c)水平,记录两组患者不良反应发生。结果两组治疗后血糖水平同治疗前相比差异显著(P<0.05),治疗后组间对比无明显差异(P>0.05);观察组不良反应发生率为8.11%低于对照组的23.32%,对比差异显著(P<0.05)。结论西格列汀可达到同二甲双胍相同的血糖控制效果,且采用西格列汀治疗后患者不良反应少。Objective To investigate the efficacy and safety of Sig Leo Dean in the treatment of newly diagnosed type 2 diabetes.Methods 74 patients with newly diagnosed type 2 diabetes were divided into the control group（37 cases） and the observation group（37 cases） of the control group（cases）.In the two groups of patients before and after treatment,fasting blood glucose（FPG）,postprandial 2h blood glucose（2h PG）,glycosylated hemoglobin（Hb A1c） levels,adverse reactions occurred in the two groups.Results The blood glucose level of the two groups were significantly different compared with that before treatment（P〈0.05）,the difference between the groups was not significantly different（P〈0.05）,the incidence of adverse reactions in the observation group was 23.32% lower than that of the control group,the difference was significant（P〈0.05）.Conclusion Sitagliptin can reached with metformin the same blood sugar control effect and treated with sitagliptin treatment with less adverse reaction.

关 键 词：2型糖尿病 西格列汀 二甲双胍 

分 类 号：R587.1[医药卫生—内分泌]